SE465676B - Flavolignanderivat, saett att framstaella detta och ett farmaceutiskt medel - Google Patents

Flavolignanderivat, saett att framstaella detta och ett farmaceutiskt medel

Info

Publication number
SE465676B
SE465676B SE8505487A SE8505487A SE465676B SE 465676 B SE465676 B SE 465676B SE 8505487 A SE8505487 A SE 8505487A SE 8505487 A SE8505487 A SE 8505487A SE 465676 B SE465676 B SE 465676B
Authority
SE
Sweden
Prior art keywords
silibinin
ethyl acetate
animals
burns
derivatives
Prior art date
Application number
SE8505487A
Other languages
English (en)
Swedish (sv)
Other versions
SE8505487L (sv
SE8505487D0 (sv
Inventor
R Braatz
K Goerler
G Halbach
H Soicke
K Schmidt
Original Assignee
Madaus Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madaus Ag filed Critical Madaus Ag
Publication of SE8505487D0 publication Critical patent/SE8505487D0/xx
Publication of SE8505487L publication Critical patent/SE8505487L/xx
Publication of SE465676B publication Critical patent/SE465676B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Silicon Compounds (AREA)
SE8505487A 1984-11-22 1985-11-20 Flavolignanderivat, saett att framstaella detta och ett farmaceutiskt medel SE465676B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19843442639 DE3442639A1 (de) 1984-11-22 1984-11-22 Flavolignanderivate, verfahren zu deren herstellung und arzneimittel, die diese verbindungen enthalten

Publications (3)

Publication Number Publication Date
SE8505487D0 SE8505487D0 (sv) 1985-11-20
SE8505487L SE8505487L (sv) 1986-05-23
SE465676B true SE465676B (sv) 1991-10-14

Family

ID=6250903

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8505487A SE465676B (sv) 1984-11-22 1985-11-20 Flavolignanderivat, saett att framstaella detta och ett farmaceutiskt medel

Country Status (29)

Country Link
JP (1) JPS61143377A (hu)
KR (1) KR870001020B1 (hu)
AR (1) AR240931A1 (hu)
AT (1) AT393268B (hu)
BE (1) BE903693A (hu)
CA (1) CA1337124C (hu)
CH (1) CH659473A5 (hu)
CS (1) CS273610B2 (hu)
DD (1) DD259191A1 (hu)
DE (1) DE3442639A1 (hu)
DK (1) DK164865C (hu)
EG (1) EG19424A (hu)
ES (1) ES8609311A1 (hu)
FI (1) FI84064C (hu)
FR (1) FR2573427B1 (hu)
GB (1) GB2167414B (hu)
HU (1) HU195503B (hu)
IE (1) IE58791B1 (hu)
IT (1) IT1190426B (hu)
LU (1) LU86163A1 (hu)
MX (1) MX168415B (hu)
NL (1) NL192387C (hu)
NO (1) NO160205C (hu)
PL (1) PL146890B1 (hu)
PT (1) PT81532B (hu)
SE (1) SE465676B (hu)
SU (1) SU1436875A3 (hu)
YU (1) YU43689B (hu)
ZA (1) ZA858951B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8716918D0 (en) * 1987-07-17 1987-08-26 Inverni Della Beffa Spa Soluble derivatives of silybin
US5262439A (en) * 1992-04-30 1993-11-16 The Regents Of The University Of California Soluble analogs of probucol
BRPI0608402B8 (pt) * 2005-03-11 2021-05-25 Armaron Bio Pty Ltd compostos de flavonóide e composições compreendendo os mesmos
CN102300570B (zh) * 2007-11-15 2015-01-14 马道斯有限责任公司 用于治疗肝炎的水飞蓟宾组分
RU2482844C2 (ru) * 2007-11-15 2013-05-27 Мадаус Гмбх Силибининовый компонент для лечения гепатита
CA2761656C (en) * 2009-05-14 2017-02-07 Lucio Claudio Rovati Amorphous silibinin for the treatment of viral hepatitis
AU2013286721B2 (en) 2012-07-05 2018-04-26 Nutramax Laboratories, Inc. Compositions comprising a sulforaphane or a sulforaphane precursor and milk thistle extract or powder
CN103113359B (zh) * 2013-02-22 2016-01-06 西安安健药业有限公司 水飞蓟宾二偏琥珀酸酯及其药用盐
CN103193768B (zh) * 2013-02-22 2016-03-30 西安安健药业有限公司 治疗肝病的水飞蓟宾二偏琥珀酸酯异构体
CN103172622B (zh) * 2013-02-22 2015-11-04 西安安健药业有限公司 水飞蓟宾二偏琥珀酸酯的活性异构体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963318A1 (de) * 1969-12-17 1971-06-24 Schwabe Willmar Gmbh & Co Silybinhalbester der Bernsteinsaeure und der Phthalsaeure,ihre Salze mit pharmakologisch vertraglichen Basen,Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneipraeparaten

Also Published As

Publication number Publication date
FI854535A (fi) 1986-05-23
PT81532A (de) 1985-12-01
CS273610B2 (en) 1991-03-12
IE58791B1 (en) 1993-11-17
LU86163A1 (de) 1986-03-24
GB2167414B (en) 1989-01-11
GB2167414A (en) 1986-05-29
PL256374A1 (en) 1986-12-02
BE903693A (fr) 1986-05-22
FR2573427A1 (fr) 1986-05-23
AR240931A1 (es) 1991-03-27
DK164865C (da) 1993-01-18
CS837885A2 (en) 1990-08-14
DD259191A1 (de) 1988-08-17
NO160205B (no) 1988-12-12
FI854535A0 (fi) 1985-11-18
NL192387B (nl) 1997-03-03
DK537785A (da) 1986-05-23
FI84064B (fi) 1991-06-28
IE852808L (en) 1986-05-22
HUT40114A (en) 1986-11-28
SU1436875A3 (ru) 1988-11-07
ES549116A0 (es) 1986-09-01
YU178685A (en) 1988-02-29
IT8522932A0 (it) 1985-11-21
CH659473A5 (de) 1987-01-30
IT1190426B (it) 1988-02-16
DE3442639C2 (hu) 1989-08-10
FI84064C (fi) 1991-10-10
FR2573427B1 (fr) 1989-03-10
ZA858951B (en) 1986-08-27
PL146890B1 (en) 1989-03-31
DK164865B (da) 1992-08-31
DE3442639A1 (de) 1986-05-22
GB8528226D0 (en) 1985-12-18
ATA337185A (de) 1991-02-15
EG19424A (en) 1995-02-28
NL192387C (nl) 1997-07-04
SE8505487L (sv) 1986-05-23
YU43689B (en) 1989-10-31
AT393268B (de) 1991-09-25
PT81532B (pt) 1987-11-11
ES8609311A1 (es) 1986-09-01
DK537785D0 (da) 1985-11-21
SE8505487D0 (sv) 1985-11-20
HU195503B (en) 1988-05-30
NO854655L (no) 1986-05-23
MX168415B (es) 1993-05-24
NL8503171A (nl) 1986-06-16
JPS61143377A (ja) 1986-07-01
NO160205C (no) 1989-03-22
AR240931A2 (es) 1991-03-27
KR870001020B1 (ko) 1987-05-23
JPH0432073B2 (hu) 1992-05-28
KR860004056A (ko) 1986-06-16
CA1337124C (en) 1995-09-26

Similar Documents

Publication Publication Date Title
US4764508A (en) Complexes of flavanolignans with phospholipids, preparation thereof and associated pharmaceutical compositions
SE465676B (sv) Flavolignanderivat, saett att framstaella detta och ett farmaceutiskt medel
US3988446A (en) Glycerides with anti-inflammatory properties
JP3075358B2 (ja) 肝機能改善剤
CA2355776C (en) Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
FR2529081A1 (fr) Composition therapeutique a base d'acide 5-hydroxydecanoique ou d'un de ses derives pour le traitement des maladies cardiovasculaires
JPH10218769A (ja) 抗潰瘍剤
US3463861A (en) Compositions and method of treating mycobacterium tuberculosis with 2,2'-(ethylenediimino)-di-1-butanols
US4883813A (en) Method of treating inflammation in mammals utilizing ketobutyrolactones and furylbutyrolactones
EP0121856A2 (de) Verwendung von Pyrazolonderivaten bei der Bekämpfung des Wachstums von Tumorzellen und der Metastasenbildung, Arzneimittel hierfür und Verfahren zu deren Herstellung
SI8511786A8 (sl) Postopek za pripravo derivatov silibinina
EP1359926B1 (en) An anti-diabetic agent obtained from the plant humboldtia decurrens and a process for preparing the same
CA1336096C (en) Isolation of castanospermine and its use as an antidiabetic agent
JPS58208225A (ja) 抗腫瘍剤
JPH0220612B2 (hu)

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8505487-2

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8505487-2

Format of ref document f/p: F